Clinical Research Directory

Inclusion Criteria: 1. Genetically confirmed Huntington's disease with HTT CAG repeat length of 40 or greater 2. Unified Huntington's Disease Rating Scale Total Maximal Chorea score of 8 or higher on a scale of 0 to 28, with higher scores indicating more severe chorea 3. Huntington's Disease Integrated Staging System stage 2 or 3 4. Willing to participate and provide informed consent 5. Have a reliable caregiver available 6. No severe cognitive impairment that would preclude reliable reporting of adverse events or efficacy during treatment Exclusion Criteria: 1. History of self-injury, aggressive behavior, or unstable psychiatric disorders 2. History of head injury or neurosurgical procedure 3. Presence of intracranial implants, metallic foreign bodies, cochlear implants, or cardiac pacemakers 4. Severe systemic disease, pregnancy, or breastfeeding 5. Contraindications to magnetic resonance imaging, ultrasound, or anesthesia 6. Prior treatment with electroconvulsive therapy, transcranial magnetic stimulation, transcranial direct current stimulation, transcranial alternating current stimulation, or other neuromodulation therapies within the past 3 years 7. Severe brain atrophy with unclear external globus pallidus structure on MRI 8. Concurrent participation in another interventional clinical trial 9. Any other condition that, in the opinion of the investigator, would preclude participation